SYS-CON MEDIA Authors: Sean Houghton, Glenn Rossman, Ignacio M. Llorente, Xenia von Wedel, Peter Silva

News Feed Item

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

NEW YORK, March 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
http://www.reportlinker.com/p02052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -
- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
- In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
- A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
- Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
- Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions
- In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
- Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents
1 Table of Contents 5

1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 8
2.3 Symptoms 9
2.4 Etiology 10
2.5 Pathophysiology 10
2.6 Co-morbidities/Complications 11
2.7 Diagnosis 11
2.8 Prognosis 11
2.9 Treatment Efficacy 11
2.10 Treatment Options 12
2.10.1 Ion Channel Modulators 12
2.10.2 GABA-ergic Facilitation 12
2.10.3 Excitatory Amino Acid Inhibitors 12
2.10.4 Synaptic Modulators 12
2.11 Non-pharmacological Management 13
2.11.1 Lobectomy and Lesionectomy 13
2.11.2 Ketogenic Diet and Modified Atkins Diet 13

2.11.3 Vagus Nerve Stimulation 13
3 Epilepsy Therapeutic Landscape 14
3.1 Overview 14
3.2 Lyrica (pregabalin) 14
3.3 Lamictal (lamotrigine) 15
3.4 Keppra (levetiracetam) 16
3.5 Zonegran (zonisamide) 18
3.6 Vimpat (lacosamide) 19
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 21
3.8 Fycompa (perampanel) 21
3.9 Trobalt/Potiga (ezogabine/retigabine) 22
3.10 Banzel/Inovelon (rufinamide) 23
3.11 Comparative Efficacy and Safety of Marketed Products 23
4 Pipeline for Epilepsy Therapeutics 26
4.1 Overall Pipeline 26
4.2 Pipeline by Mechanism of Action 28
4.3 Clinical Trials 29
4.3.1 Failure Rate 29
4.3.2 Patient Enrolment and Clinical Trial Size 31
4.3.3 Clinical Trial Duration 32
4.4 Promising Pipeline Candidates 33
4.4.1 Brivaracetam – UCB 33
4.4.2 Ganaxolone – Marinus Pharmaceuticals 33
5 Epilepsy Therapeutics Market Forecast to 2019 34
5.1 Geographical Markets 34
5.1.1 Key Asia-Pacific Markets 34
5.1.2 China 36

5.1.3 India 38
5.1.4 Japan 40
5.1.5 Australia 42
5.2 Drivers and Barriers 44
5.2.1 Drivers 44
5.2.2 Barriers 44
6 Deals and Strategic Consolidations 45
6.1 Deals Analysis 45
6.2 Research and Development Co-development Agreements 47
6.3 Research and Development Licensing Agreements 48
7 Appendix 50
7.1 Abbreviations 50
7.2 References 51
7.3 References for Heat Maps 55
7.4 Pipeline Products by Phase 56
7.4.1 Discovery 56
7.4.2 Preclinical 57
7.4.3 IND-filed and Phase 0 58
7.4.4 Phase I 58
7.4.5 Phase II 59
7.4.6 Phase III 60
7.4.7 Pre-registration 60
7.5 Market Forecasting Data Tables to 2019 61
7.5.1 Asia-Pacific 61
7.5.2 China 61
7.5.3 India 61
7.5.4 Japan 62
7.5.5 Australia 62

7.6 Research Methodology 62
7.6.1 Coverage 62
7.6.2 Secondary Research 63
7.6.3 Primary Research 63
7.6.4 Therapeutic Landscape 63
7.6.5 Geographical Landscape 66
7.6.6 Pipeline Analysis 66
7.7 Expert Panel Validation 66
7.8 Contact Us 66
7.9 Disclaimer 66

1.1 List of Tables
Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013 8
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References 55
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013 56
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013 57
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013 58
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013 58
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013 59
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013 60
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013 60
Table 10: Epilepsy Therapeutics, Asia-Pacific, Market Forecast, 2012–2019 61
Table 11: Epilepsy Therapeutics, China, Market Forecast, 2012–2019 61
Table 12: Epilepsy Therapeutics, India, Market Forecast, 2012–2019 61
Table 13: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019 62
Table 14: Epilepsy Therapeutics, Australia, Market Forecast, 2012–2019 62

1.2 List of Figures
Figure 1: Epilepsy Therapeutics, Epidemiology, Asia-Pacific, 2012 9
Figure 2: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013 15
Figure 3: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013 16
Figure 4: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013 17
Figure 5: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013 18
Figure 6: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013 20
Figure 7: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 24
Figure 8: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013 27
Figure 9: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013 28
Figure 10: Epilepsy Therapeutics, Global, Clinical Trial Failure Rate, 2013 30
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013 31
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013 32
Figure 13: Epilepsy Therapeutics, Asia-Pacific, Market Size, 2012–2019 35
Figure 14: Epilepsy Therapeutics, China, Market Size, 2012–2019 37
Figure 15: Epilepsy Therapeutics, India, Market Size, 2012–2019 39
Figure 16: Epilepsy Therapeutics, Japan, Market Size, 2012–2019 41
Figure 17: Epilepsy Therapeutics, Australia, Market Size, 2012–2019 43
Figure 18: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013 45
Figure 19: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013 46
Figure 20: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013 47
Figure 21: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013 48
Figure 22: GBI Research Market Forecasting Model 65

To order this report: Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
http://www.reportlinker.com/p02052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
“We help people build clusters, in the classical sense of the cluster. We help people put a full stack on top of every single one of those machines. We do the full bare metal install," explained Greg Bruno, Vice President of Engineering and co-founder of StackIQ, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The cloud is becoming the de-facto way for enterprises to leverage common infrastructure while innovating and one of the biggest obstacles facing public cloud computing is security. In his session at 15th Cloud Expo, Jeff Aliber, a global marketing executive at Verizon, discussed how the best place for web security is in the cloud. Benefits include: Functions as the first layer of defense Easy operation –CNAME change Implement an integrated solution Best architecture for addressing network-l...
Mobile commerce traffic is surpassing desktop, yet less than 20% of sales in the U.S. are mobile commerce sales. In his session at 15th Cloud Expo, Dan Franklin, Segment Manager, Commerce, at Verizon Digital Media Services, defined mobile devices and discussed how next generation means simplification. It means taking your digital content and turning it into instantly gratifying experiences.
“In the past year we've seen a lot of stabilization of WebRTC. You can now use it in production with a far greater degree of certainty. A lot of the real developments in the past year have been in things like the data channel, which will enable a whole new type of application," explained Peter Dunkley, Technical Director at Acision, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Windstream, a leading provider of advanced network and cloud communications, has been named “Silver Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. Windstream (Nasdaq: WIN), a FORTUNE 500 and S&P 500 company, is a leading provider of advanced network communications, including cloud computing and managed services, to businesses nationwide. The company also offers broadband, p...
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud strategy and programs. In this Power Panel at 15th Cloud Expo (http://www.CloudComputingExpo.com...
Verizon Enterprise Solutions is simplifying the cloud-purchasing experience for its clients, with the launch of Verizon Cloud Marketplace, a key foundational component of the company's robust ecosystem of enterprise-class technologies. The online storefront will initially feature pre-built cloud-based services from AppDynamics, Hitachi Data Systems, Juniper Networks, PfSense and Tervela. Available globally to enterprises using Verizon Cloud, Verizon Cloud Marketplace provides a one-stop shop fo...
Leysin American School is an exclusive, private boarding school located in Leysin, Switzerland. Leysin selected an OpenStack-powered, private cloud as a service to manage multiple applications and provide development environments for students across the institution. Seeking to meet rigid data sovereignty and data integrity requirements while offering flexible, on-demand cloud resources to users, Leysin identified OpenStack as the clear choice to round out the school's cloud strategy. Additional...
The Internet of Things is not new. Historically, smart businesses have used its basic concept of leveraging data to drive better decision making and have capitalized on those insights to realize additional revenue opportunities. So, what has changed to make the Internet of Things one of the hottest topics in tech? In his session at @ThingsExpo, Chris Gray, Director, Embedded and Internet of Things, discussed the underlying factors that are driving the economics of intelligent systems. Discover ...
The move in recent years to cloud computing services and architectures has added significant pace to the application development and deployment environment. When enterprise IT can spin up large computing instances in just minutes, developers can also design and deploy in small time frames that were unimaginable a few years ago. The consequent move toward lean, agile, and fast development leads to the need for the development and operations sides to work very closely together. Thus, DevOps become...

ARMONK, N.Y., Nov. 20, 2014 /PRNewswire/ --  IBM (NYSE: IBM) today announced that it is bringing a greater level of control, security and flexibility to cloud-based application development and delivery with a single-tenant version of Bluemix, IBM's

"Our premise is Docker is not enough. That's not a bad thing - we actually love Docker. At ActiveState all our products are based on open source technology and Docker is an up-and-coming piece of open source technology," explained Bart Copeland, President & CEO of ActiveState Software, in this SYS-CON.tv interview at DevOps Summit at Cloud Expo®, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Media announced today that Aruna Ravichandran, VP of Marketing, Application Performance Management and DevOps at CA Technologies, has joined DevOps Journal’s authors. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information to DevOps professionals who are transforming the way enterprise IT is done. Aruna's inaugural article "Four Essential Cultural Hacks for DevOps Newbies" discusses how to demonstrate the...